Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Announcements
share announcement

Announcements

23 February 2024
Journal of Personalized Medicine | Most Viewed Papers in 2022 in the Section “Pharmacogenetics”


We are pleased to invite you to read the most viewed papers in 2022 in the Journal of Personalized Medicine (JPM, ISSN: 2075-4426) in the Section “Pharmacogenetics”. The list of papers is as follows:

1. “Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care”
by Elpiniki Rentzeperi, Stavroula Pegiou, Theocharis Koufakis, Maria Grammatiki and Kalliopi Kotsa
J. Pers. Med. 2022, 12(3), 454; https://doi.org/10.3390/jpm12030454
Available online: https://www.mdpi.com/2075-4426/12/3/454

2. “Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis”
by Iris A. L. Silva, Onofrio Laselva and Miquéias Lopes-Pacheco
J. Pers. Med. 2022, 12(8), 1321; https://doi.org/10.3390/jpm12081321
Available online: https://www.mdpi.com/2075-4426/12/8/1321

3. “Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes”
by Artemis Kyriakidou, Angeliki V. Kyriazou, Theocharis Koufakis, Yiannis Vasilopoulos, Maria Grammatiki, Xanthippi Tsekmekidou, Iakovos Avramidis, Stefanos Baltagiannis, Dimitrios G. Goulis, Pantelis Zebekakis et al.
J. Pers. Med. 2022, 12(3), 424; https://doi.org/10.3390/jpm12030424
Available online: https://www.mdpi.com/2075-4426/12/3/424 

4. “The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation”
by Kimberly S. Foss, Julianne M. O’Daniel, Jonathan S. Berg, Sabrina N. Powell, Rosemary Jean Cadigan, Kristine J. Kuczynski, Laura V. Milko, Katherine W. Saylor, Megan Roberts, Karen Weck et al.
J. Pers. Med. 2022, 12(5), 692; https://doi.org/10.3390/jpm12050692
Available online: https://www.mdpi.com/2075-4426/12/5/692

5. “CFTR and Gastrointestinal Cancers: An Update”
by Rahul Bhattacharya, Zachary Blankenheim, Patricia M. Scott and Robert T. Cormier
J. Pers. Med. 2022, 12(6), 868; https://doi.org/10.3390/jpm12060868
Available online: https://www.mdpi.com/2075-4426/12/6/868

6. “Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study”
by Antonio Del Casale, Leda Marina Pomes, Luca Bonanni, Federica Fiaschè, Clarissa Zocchi, Alessio Padovano, Ottavia De Luca, Gloria Angeletti, Roberto Brugnoli, Paolo Girardi et al.
J. Pers. Med. 2022, 12(2), 316; https://doi.org/10.3390/jpm12020316
Available online: https://www.mdpi.com/2075-4426/12/2/316

7. “Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease”
by Panagiotis I. Georgianos, Vasilios Vaios, Stefanos Roumeliotis, Konstantinos Leivaditis, Theodoros Eleftheriadis and Vassilios Liakopoulos
J. Pers. Med. 2022, 12(2), 223; https://doi.org/10.3390/jpm12020223
Available online: https://www.mdpi.com/2075-4426/12/2/223

8. “Development and Validation of the Minnesota Assessment of Pharmacogenomic Literacy (MAPL)”
by Josiah D. Allen, Lusi Zhang, Alyssa N. K. Johnson, Pamala A. Jacobson, Catherine A. McCarty, Amy L. Pittenger and Jeffrey R. Bishop
J. Pers. Med. 2022, 12(9), 1398; https://doi.org/10.3390/jpm12091398
Available online: https://www.mdpi.com/2075-4426/12/9/1398 

9. “Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis”
by Julie Mésinèle, Manon Ruffin, Loïc Guillot, Pierre-Yves Boëlle, Harriet Corvol and on behalf of the French CF Modifier Gene Study Investigators
J. Pers. Med. 2022, 12(2), 252; https://doi.org/10.3390/jpm12020252
Available online: https://www.mdpi.com/2075-4426/12/2/252

10. “Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy”
by Anna C. Virgili Manrique, Juliana Salazar, María Jesús Arranz, Silvia Bagué, Ruth Orellana, Antonio López-Pousa, Paula Cerdà, Isidre Gracia, Katarina Majercakova, Ana Peiró et al.
J. Pers. Med. 2022, 12(4), 618; https://doi.org/10.3390/jpm12040618
Available online: https://www.mdpi.com/2075-4426/12/4/618

More News...
Back to TopTop